These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

265 related items for PubMed ID: 24472740

  • 1. CRF type 1 receptors of the medial amygdala modulate inhibitory avoidance responses in the elevated T-maze.
    Vicentini JE, Céspedes IC, Nascimento JO, Bittencourt JC, Viana MB.
    Horm Behav; 2014 Mar; 65(3):195-202. PubMed ID: 24472740
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. The blockage of ventromedial hypothalamus CRF type 2 receptors impairs escape responses in the elevated T-maze.
    Silva MSCF, Souza TMO, Pereira BA, Ribeiro DA, Céspedes IC, Bittencourt JC, Viana MB.
    Behav Brain Res; 2017 Jun 30; 329():41-50. PubMed ID: 28435125
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Anxiogenic and antinociceptive effects induced by corticotropin-releasing factor (CRF) injections into the periaqueductal gray are modulated by CRF1 receptor in mice.
    Miguel TT, Nunes-de-Souza RL.
    Horm Behav; 2011 Aug 30; 60(3):292-300. PubMed ID: 21723867
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The behavioural and electrophysiological effects of CRF in rat frontal cortex.
    Zieba B, Grzegorzewska M, Brański P, Domin H, Wierońska JM, Hess G, Smiałowska M.
    Neuropeptides; 2008 Aug 30; 42(5-6):513-23. PubMed ID: 18617263
    [Abstract] [Full Text] [Related]

  • 11. Brain penetrance, receptor occupancy and antistress in vivo efficacy of a small molecule corticotropin releasing factor type I receptor selective antagonist.
    Heinrichs SC, De Souza EB, Schulteis G, Lapsansky JL, Grigoriadis DE.
    Neuropsychopharmacology; 2002 Aug 30; 27(2):194-202. PubMed ID: 12093593
    [Abstract] [Full Text] [Related]

  • 12. Corticotropin releasing factor enhances attentional function as assessed by the five-choice serial reaction time task in rats.
    Ohmura Y, Yamaguchi T, Futami Y, Togashi H, Izumi T, Matsumoto M, Yoshida T, Yoshioka M.
    Behav Brain Res; 2009 Mar 17; 198(2):429-33. PubMed ID: 19084036
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Neonatal thyroxine treatment: changes in the number of corticotropin-releasing-factor (CRF) and neuropeptide Y (NPY) containing neurons and density of tyrosine hydroxylase positive fibers (TH) in the amygdala correlate with anxiety-related behavior of wistar rats.
    Yilmazer-Hanke DM, Hantsch M, Hanke J, Schulz C, Faber-Zuschratter H, Schwegler H.
    Neuroscience; 2004 Mar 17; 124(2):283-97. PubMed ID: 14980379
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Anxiogenic-like effect of corticotropin-releasing factor receptor 2 antisense oligonucleotides infused into rat brain.
    Isogawa K, Akiyoshi J, Tsutsumi T, Kodama K, Horinouti Y, Nagayama H.
    J Psychopharmacol; 2003 Dec 17; 17(4):409-13. PubMed ID: 14870953
    [Abstract] [Full Text] [Related]

  • 19. Corticotropin-releasing factor in ventromedial prefrontal cortex mediates avoidance of a traumatic stress-paired context.
    Schreiber AL, Lu YL, Baynes BB, Richardson HN, Gilpin NW.
    Neuropharmacology; 2017 Feb 17; 113(Pt A):323-330. PubMed ID: 27235163
    [Abstract] [Full Text] [Related]

  • 20. Receptor binding, behavioral, and electrophysiological profiles of nonpeptide corticotropin-releasing factor subtype 1 receptor antagonists CRA1000 and CRA1001.
    Okuyama S, Chaki S, Kawashima N, Suzuki Y, Ogawa S, Nakazato A, Kumagai T, Okubo T, Tomisawa K.
    J Pharmacol Exp Ther; 1999 May 17; 289(2):926-35. PubMed ID: 10215672
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.